secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001193125-25-193238
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M
--------------------------------------------------------------------------------

- Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.
- Upfront $210M; up to $100M development/regulatory milestones and $220M commercial milestones.
- Royalties on ex-US net sales: mid-teens to low-twenties percent.
- Cash runway extended by at least 12 months; expects funding into 2030 under current plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/0001193125-25-193238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/d800731d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-193238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer